Company: BSX
Filing Date: 2025-03-19
Form Type: DEF 14A
Source: 0000885725-25-000017
Chunk: 3

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-03-19
Form: DEF 14A
Chunk 3
---
 appendage closure (LAAC) devices; at the same time, we have disrupted the fastest-growing segment of AF treatment with our explosive entry into pulsed field ablation (PFA). We are committed to our category leadership strategy in both areas, driven by smart investments, clinical evidence and commercial excellence.

#### Leading an expansion in LAAC
Ten years ago, we introduced to physicians in the United States our WATCHMAN™ LAAC technology for patients with non-valvular AF (NVAF). This year we celebrated the milestone of having helped physicians treat more than 500,000 patients globally.

In 2024 we continued expanding our reach with our newest-generation WATCHMAN FLX™ Pro LAAC Device, as well as with the FDA clearance and U.S. launch of the WATCHMAN TruSteer™ Access System, a steerable sheath designed to improve implant success. We also announced the results of the global OPTION clinical trial for our WATCHMAN technology. Patients with AF who are at high to moderate stroke risk are typically prescribed long-term anticoagulation medications after an ablation. The OPTION clinical trial found that for high-risk patients with NVAF who have undergone an ablation, receiving the WATCHMAN FLX device reduced their stroke risk just as effectively as oral anticoagulants, and with significantly less bleeding risk. Our goal is to make the WATCHMAN device a frontline therapy for this subset of patients and ultimately, a frontline therapy for a broader number of patients with AF who are at risk of stroke.

### Innovation in high-growth AF procedures
The January 2024 FDA approval of our FARAPULSE™ Pulsed Field Ablation (PFA) System kicked off one of our most exciting years at Boston Scientific. In under a year, we have transformed the fast-growing AF ablation market with our unique PFA technology. Its rapid adoption in Europe and the United States, plus launches in China and Japan, have swiftly positioned us as a leading player in PFA with more than 200,000 patients already treated with the FARAPULSE PFA System. This success drew upon our global teams’ talents for scientific innovation, manufacturing logistics and commercial excellence, and is a testament to their incredible skill.

As part of our plan to continue our category leadership strategy in AF ablation, we also launched a next-generation of cardiac mapping for visualization during FARAPULSE procedures: the FARAWAVE™ NAV Ablation Catheter, our new FARAVIEW™ Software Module, and the OPAL™ HDx